What does this research mean for the field?

Successful clinical translation of nanomaterial-based drug delivery systems requires a structured roadmap that prioritizes biologically predictive design, scalable manufacturing, early regulatory alignment, and clinically meaningful benefit over unnecessary structural complexity. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the clinical, biological, and regulatory factors governing nanomaterial-based drug delivery systems and establish a roadmap for successful clinical translation.

August 30, 2026Biomedicine & PharmacotherapyOpen Access

Nanomaterial-based drug delivery systems: From intelligent delivery to clinical translation and precision nanomedicine

View Full Paper

Ask AI

Bookmark

Authors

YLYi LiChengdu Medical College RLRui LuoSichuan University YLYuxuan LiChengdu Medical College

Discussion

Member takes

Overview

Review evaluates nanomaterial-based drug delivery platforms across clinical and regulatory landscapes, highlighting translational strategies to advance precision medicine.

Key Points

To evaluate the clinical, biological, and regulatory factors governing nanomaterial-based drug delivery systems and establish a roadmap for successful clinical translation.
Conducted a cross-platform comparison of lipid nanoparticles, polymeric nanoparticles, inorganic nanomaterials, extracellular vesicles, and biomimetic nanocarriers.
Evaluated targeting mechanisms, nano-bio interactions, computational design tools, and regulatory guidelines across the United States, Europe, Japan, and China.
Identified that clinical success depends primarily on biological barrier navigation, protein-corona evolution, and immune recognition rather than carrier structural complexity alone.
Synthesized historical attrition rates and commercial successes into a translational framework emphasizing scalable manufacturing, predictive preclinical models, and harmonized regulatory compliance.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a93f00a6c1a8fb52e79c0e5 https://doi.org/10.1016/j.biopha.2026.119888

View Full Paper

Ask AI

Bookmark

August 30, 2026Biomedicine & PharmacotherapyOpen Access

Nanomaterial-based drug delivery systems: From intelligent delivery to clinical translation and precision nanomedicine

View Full Paper

Ask AI

Bookmark

Authors

YLYi LiChengdu Medical College RLRui LuoSichuan University YLYuxuan LiChengdu Medical College

Discussion

Member takes

Overview

Review evaluates nanomaterial-based drug delivery platforms across clinical and regulatory landscapes, highlighting translational strategies to advance precision medicine.

Key Points

To evaluate the clinical, biological, and regulatory factors governing nanomaterial-based drug delivery systems and establish a roadmap for successful clinical translation.
Conducted a cross-platform comparison of lipid nanoparticles, polymeric nanoparticles, inorganic nanomaterials, extracellular vesicles, and biomimetic nanocarriers.
Evaluated targeting mechanisms, nano-bio interactions, computational design tools, and regulatory guidelines across the United States, Europe, Japan, and China.
Identified that clinical success depends primarily on biological barrier navigation, protein-corona evolution, and immune recognition rather than carrier structural complexity alone.
Synthesized historical attrition rates and commercial successes into a translational framework emphasizing scalable manufacturing, predictive preclinical models, and harmonized regulatory compliance.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a93f00a6c1a8fb52e79c0e5 https://doi.org/10.1016/j.biopha.2026.119888

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark